Center for Innovative Cancer Research, Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Faculty of Medicine, University of Ottawa , Ottawa, ON , Canada.
Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014.
Oncolytic viruses (OVs) not only kill cancer cells by direct lysis but also generate a significant anti-tumor immune response that allows for prolonged cancer control and in some cases cures. How to best stimulate this effect is a subject of intense investigation in the OV field. While pharmacological manipulation of the cellular innate anti-viral immune response has been shown by several groups to improve viral oncolysis and spread, it is increasingly clear that pharmacological agents can also impact the anti-tumor immune response generated by OVs and related tumor vaccination strategies. This review covers recent progress in using pharmacological agents to improve the activity of OVs and their ability to generate robust anti-tumor immune responses.
溶瘤病毒 (OVs) 不仅可以通过直接裂解杀死癌细胞，还可以产生显著的抗肿瘤免疫反应，从而实现对癌症的长期控制，甚至在某些情况下可以治愈癌症。如何最好地刺激这种效应是 OV 领域中一个研究热点。虽然已有多个研究小组证明，通过药理学手段来调节细胞固有抗病毒免疫反应，可以提高病毒的溶瘤作用和传播能力，但越来越明显的是，药理学药物也会影响 OV 产生的抗肿瘤免疫反应以及相关的肿瘤疫苗策略。本文综述了近年来利用药理学手段来提高 OV 的活性及其产生强大抗肿瘤免疫反应的能力的最新进展。
